Humana Inc.
0J6Z.L
London Stock Exchange328.66
USD
+2.51
- -
Humana Inc.
0J6Z.L
(London Stock Exchange)
Recent
price
328.66
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Humana Inc. Humana Inc. provides health insurance and integrated healthcare services to approximately 17 million members, primarily through its Insurance and CenterWell segments; the Insurance segment offers Medicare Advantage plans including prescription drug coverage, supplemental dental, vision and hearing benefits, Medicaid managed care, military TRICARE services under the Humana Military Healthcare Services subsidiary, group health insurance, and specialty products such as life and supplemental benefits; the CenterWell segment delivers primary care through senior-focused clinics, pharmacy solutions via CenterWell Pharmacy, and home health and hospice services. Founded in 1961 and headquartered in Louisville, Kentucky, the company operates nationwide across the United States with a focus on seniors, low-income individuals, employer groups, and military families, emphasizing value-based care, digital health tools, and whole-person wellness programs. Humana Inc. reports revenue exceeding $100 billion annually and employs over 65,000 people as the fourth-largest health insurer in the U.S. In recent developments, Humana partners with HOPCo effective October 2025 to expand its musculoskeletal population health program for Arizona members, utilizing integrated care systems and digital tools; the company raised its 2025 revenue guidance to at least $128 billion amid medical cost controls and CenterWell growth, while targeting Medicare Advantage margin improvements to double by 2026 and achieve top-quartile Stars ratings by 2028; it continues portfolio streamlining following its 2023 exit from employer commercial medical plans and prior adjustments including the 2022 sale of a majority stake in Kindred at Home.